Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001654954-25-001501
Filing Date
2025-02-14
Accepted
2025-02-14 08:32:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6100
2 JOINT FILING AGREEMENT camber_ex11.htm EX-1 4614
  Complete submission text file 0001654954-25-001501.txt   12530
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Subject) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-48577 | Film No.: 25623478
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 101 HUNTINGTON AVENUE SUITE 2101 BOSTON MA 02199
Business Address 101 HUNTINGTON AVENUE SUITE 2101 BOSTON MA 02199 617-717-6600
Camber Capital Management LP (Filed by) CIK: 0001444043 (see all company filings)

EIN.: 421693587 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A